GAIA
Company Overview
GAIA is focused on the development of evidence-based, safe, and accessible digital therapeutics that help patients restore and maintain their mental and physical health.
With over 20 years of experience and more than 70 products, GAIA's digital therapeutics have clinically proven effectiveness supported by more than 19 randomized controlled trials (RCTs) and 2 meta-analyses.
Mission and Expertise
GAIA aims to develop digital therapeutics that offer physicians, therapists, payers, and patients similar effect sizes, safety profiles, and convenience as pharmaceutical solutions.
The team comprises multidisciplinary experts including physicians, psychotherapists, clinical scientists, IT and software engineers, regulatory affairs experts, and market access specialists to develop, launch, and maintain top-class products.
Clinical Research
GAIA emphasizes RCT evidence, extensively testing their products through unbiased and professionally designed randomized controlled trials.
One notable product is deprexis®, an online program for treating depression, shown in 13 RCTs and real-life clinical settings to effectively reduce symptoms with effect sizes comparable to antidepressants.